201 related articles for article (PubMed ID: 30808702)
1. HIV-1 Escape from Small-Molecule Antagonism of Vif.
Sharkey M; Sharova N; Mohammed I; Huff SE; Kummetha IR; Singh G; Rana TM; Stevenson M
mBio; 2019 Feb; 10(1):. PubMed ID: 30808702
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC.
Zuo T; Liu D; Lv W; Wang X; Wang J; Lv M; Huang W; Wu J; Zhang H; Jin H; Zhang L; Kong W; Yu X
J Virol; 2012 May; 86(10):5497-507. PubMed ID: 22379088
[TBL] [Abstract][Full Text] [Related]
3. The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation.
Donahue JP; Vetter ML; Mukhtar NA; D'Aquila RT
Virology; 2008 Jul; 377(1):49-53. PubMed ID: 18499212
[TBL] [Abstract][Full Text] [Related]
4. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
He Z; Zhang W; Chen G; Xu R; Yu XF
J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
[TBL] [Abstract][Full Text] [Related]
5. APOBEC3 degradation is the primary function of HIV-1 Vif determining virion infectivity in the myeloid cell line THP-1.
Ikeda T; Shimizu R; Nasser H; Carpenter MA; Cheng AZ; Brown WL; Sauter D; Harris RS
mBio; 2023 Aug; 14(4):e0078223. PubMed ID: 37555667
[TBL] [Abstract][Full Text] [Related]
6. Identification of dominant negative human immunodeficiency virus type 1 Vif mutants that interfere with the functional inactivation of APOBEC3G by virus-encoded Vif.
Walker RC; Khan MA; Kao S; Goila-Gaur R; Miyagi E; Strebel K
J Virol; 2010 May; 84(10):5201-11. PubMed ID: 20219919
[TBL] [Abstract][Full Text] [Related]
7. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
Russell RA; Pathak VK
J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
[TBL] [Abstract][Full Text] [Related]
8. Vpr14-88-Apobec3G fusion protein is efficiently incorporated into Vif-positive HIV-1 particles and inhibits viral infection.
Ao Z; Yu Z; Wang L; Zheng Y; Yao X
PLoS One; 2008 Apr; 3(4):e1995. PubMed ID: 18414671
[TBL] [Abstract][Full Text] [Related]
9. Regulation of Vif mRNA splicing by human immunodeficiency virus type 1 requires 5' splice site D2 and an exonic splicing enhancer to counteract cellular restriction factor APOBEC3G.
Mandal D; Exline CM; Feng Z; Stoltzfus CM
J Virol; 2009 Jun; 83(12):6067-78. PubMed ID: 19357165
[TBL] [Abstract][Full Text] [Related]
10. Multifaceted counter-APOBEC3G mechanisms employed by HIV-1 Vif.
Britan-Rosich E; Nowarski R; Kotler M
J Mol Biol; 2011 Jul; 410(5):1065-76. PubMed ID: 21763507
[TBL] [Abstract][Full Text] [Related]
11. Small-molecule inhibition of HIV-1 Vif.
Nathans R; Cao H; Sharova N; Ali A; Sharkey M; Stranska R; Stevenson M; Rana TM
Nat Biotechnol; 2008 Oct; 26(10):1187-92. PubMed ID: 18806783
[TBL] [Abstract][Full Text] [Related]
12. Identification of a critical T(Q/D/E)x5ADx2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity.
Dang Y; Wang X; York IA; Zheng YH
J Virol; 2010 Sep; 84(17):8561-70. PubMed ID: 20592083
[TBL] [Abstract][Full Text] [Related]
13. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
[TBL] [Abstract][Full Text] [Related]
14. The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells.
Casartelli N; Guivel-Benhassine F; Bouziat R; Brandler S; Schwartz O; Moris A
J Exp Med; 2010 Jan; 207(1):39-49. PubMed ID: 20038599
[TBL] [Abstract][Full Text] [Related]
15. Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function.
Albin JS; Haché G; Hultquist JF; Brown WL; Harris RS
J Virol; 2010 Oct; 84(19):10209-19. PubMed ID: 20686027
[TBL] [Abstract][Full Text] [Related]
16. Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif.
Pery E; Rajendran KS; Brazier AJ; Gabuzda D
J Virol; 2009 Mar; 83(5):2374-81. PubMed ID: 19109396
[TBL] [Abstract][Full Text] [Related]
17. APOBEC3G is degraded by the proteasomal pathway in a Vif-dependent manner without being polyubiquitylated.
Dang Y; Siew LM; Zheng YH
J Biol Chem; 2008 May; 283(19):13124-31. PubMed ID: 18326044
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of HIV-1 infection and replication by enhancing viral incorporation of innate anti-HIV-1 protein A3G: a non-pathogenic Nef mutant-based anti-HIV strategy.
Green LA; Liu Y; He JJ
J Biol Chem; 2009 May; 284(20):13363-13372. PubMed ID: 19324886
[TBL] [Abstract][Full Text] [Related]
19. Identification of amino acid residues in HIV-1 Vif critical for binding and exclusion of APOBEC3G/F.
Yamashita T; Kamada K; Hatcho K; Adachi A; Nomaguchi M
Microbes Infect; 2008; 10(10-11):1142-9. PubMed ID: 18603011
[TBL] [Abstract][Full Text] [Related]
20. APOBEC3G complexes decrease human immunodeficiency virus type 1 production.
Martin KL; Johnson M; D'Aquila RT
J Virol; 2011 Sep; 85(18):9314-26. PubMed ID: 21752914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]